EX-10.23 22 f8k122812a1ex10xxiii_cactus.htm CLINICAL TRIAL AGREEMENT WITH THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER, DATED MARCH 1, 2012.
Exhibit 10.23
March 1, 2012 Page 1 of 14
CLINICAL TRIAL AGREEMENT
THIS CLINICAL TRIAL AGREEMENT ("Agreement") is made by and between The University of Texas M.D. Anderson Cancer Center, a member institution of The University of Texas System " system" having a principal place of business at 1515 Holcombe Blvd. Houston, TX 77030 ("Site") and Actinium Pharmaceuticals, Inc. with an address of 391 Lafayette Street, Newark, New Jersey 07105 ("Actinium"). This Agreement is entered into this 6 th day of August 2012.
This Agreement provides for the conduct of a clinical investigation using a proprietary drug which is not, at this time, cleared for human use by the Food and Drug Administration. Any use of this drug must be pursuant to an Investigational New Drug Exemption (IND 10807) held by Actinium. Aptiv Solutions, Inc., a Delaware corporation having a principal place of business at 1925 Isaac Newton Square, Suite 100, Reston, VA 20190 ("Aptiv") has been engaged by Actinium to oversee and manage the Study.
In consideration of the mutual covenants and conditions set forth in this Agreement and for good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

1. | Definitions. When used in this Agreement, the listed terms shall have the following meanings:

| a. | "Study" means the conduct of human research using the Study Drug manufactured by Actinium on Qualified Subjects at the Site pursuant to the protocol which has been reviewed and approved by the IRB and the FDA prior to the commencement of the Study.
| b. | "Protocol" means the details of that certain clinical Study to be performed pursuant to this Agreement entitled A Phase 1/II Study of Low Dose Cytarabine and Actinium-255 Hum195 in Older Patients with Untreated Acute Myeloid Leukemia. The Protocol, including any amendments is hereby incorporated for reference purposes only and made part of this Agreement.
| c. | "IRB" means the institutional review board of Site.
| d. | "Study Drug" means the compound known as Actinium-255 Hum 195.
| e. | "Study Data" means all of the data collected and records compiled during the Study relating to the conduct of the Study and/or the Study Drug. Study Data includes without limitation, all records prepared by the Investigator and all clinical research assistants, all Case Report Forms, all Screening records, all records on Qualified Subjects, Completed Subjects, Withdrawn Subjects, Uncompleted Subjects and Non-Qualified Subjects, all Informed Consent forms, all adverse/unexpected/serious or other reportable events, and all modifications, adjustments, suggestions for improvement of the Study Drug.

| f. | "Potential Subject" is a patient or individual who could possibly participate in the Study.
| g. | "Screening" is the process of identifying Potential Subjects and of conducting the examinations and tests necessary to select Qualified Subjects for the Study.
| h. | "Qualified Subject" is a subject who, on inclusion in the treatment phase of the Study, has met all of the inclusion criteria and none of the exclusion criteria in the Protocol and has given his/her written Informed Consent to participate in the Study.
| i. | "Completed Subject" is a Qualified Subject who has completed the Study and met the minimum attendance and compliance standards in the Protocol for evaluation of the safety and effectiveness of the Study Drug.
| j. | "Withdrawn Subject" is a Qualified Subject who has been withdrawn from the Study because of treatment failure or adverse event, but who otherwise met the Protocol entry requirements.
| k. | "Uncompleted Subject" is a Qualified Subject who was initially included in the Study but who failed to complete the Study satisfactorily because of insufficient clinic attendance, poor compliance, voluntary withdrawal, and loss to follow-up or other Protocol violations.

March 1, 2012 Page 2 of 14

| 1. | "Non-Qualified Subject" is a subject who has not met the inclusion criteria as defined in the Protocol.
| m. | "Informed Consent Form" means the written form agreed upon by Actinium and the Site in conformance with all applicable FDA regulations and guidances, and approved by the IRB for use in this Study.
| n. | "Case Report Form (CRF)" means the report in the Actinuim format which is completed by the Investigator or his/her authorized designee documenting the use of the Study Drug in subjects.
| o. | "FDA" means the Food and Drug Administration of the United States Department of Health and Human Services, and any successor government agency.
| P- | "Investigator's Brochure" is a document describing the Study Drug, which is provided to the Investigator prior to the start of the Study.
| q. | "Investigator" means Farhad Ravandi-Kashani,MD

2. | Compliance with laws and procedures.

| a. | All parties shall conduct the Study in accordance with all applicable laws, regulations and guidances, as each of the foregoing may be amended from time to time. Without limiting the foregoing, the parties expressly agree to comply with 21 CFR 312 - Investigational New Drug Application, 21 CFR 50 - Protection of Human Subjects, and 21 CFR 56 — Institutional Review Boards.
| b. | The Site agrees to comply with the terms of this Agreement and all IRB and FDA procedures and applicable decisions for the Study.
3. | Scope of Study
| a. | This Study is governed by this Agreement. All parties agree that no Study Drug shall be used on a subject until the IRB and the FDA have both approved the Study. After the FDA and IRB approval, the Protocol may only be amended when: 1) there is written agreement between the Site and Actinium to amend the Protocol, and 2) any and all such amendments have been reviewed and approved by the IRB and FDA. No Protocol amendments shall be implemented until receipt of the IRB and FDA written approval. Nothing in this paragraph shall limit the Investigator's ability to act under 21 CFR 312.50, 312.60, 312.62, 312.64 (Subpart D).
| b. | The Site agrees to strictly comply with all IRB procedures and policies which govern the review, approval and conduct of this Study.
| c. | The parties agree that Screening for Qualified Subjects shall begin within thirty (30) days of receipt of the following: 1) written approval of the Study and the Informed Consent by the IRB, 2) notification by Aptiv or Actinium that the FDA has granted the Investigational New Drug Application for the Study Drug, and 3) completion of Initiation Visit of the Site by Aptiv and Actinium for Study participation. The goal of the Study is to enroll up to ten (10) Qualified Subjects per year. The Site agrees to use its reasonable best efforts to complete subject enrollment as soon as practical, after commencement of Screening at each dose group.

4. | Responsibilities of Actinium

| a. | Actinium represents and certifies that it has the authority to enter into this Agreement on its own behalf.
| b. | Actinium agrees to provide to the Site and the Investigator the information necessary to properly conduct the Study, including without limitation, the Protocol, the Investigator's Brochure and data of any prior investigations of the Study Drug. Actinium agrees to provide any new information related to the safety and efficacy of the Study Drug as such information becomes available during the course of the Study. Actinium advises the Site and the Investigator that the effectiveness and safety in humans of the Study Drug have not been fully investigated.

March 1, 2012 Page 3 of 14

| c. | Actinium shall provide, free of charge to Institution, the necessary quantity of the Study Drug. Actinium or Aptiv shall ship the Study Drug only to the Site.
| d. | Aptiv shall monitor the Study and shall require evidence that IRB review and approval are obtained.
Actinium agrees that Institution, its affiliates and all Study team members shall have the sole authority over the clinical care of the Study subjects and nothing in this Agreement shall prevent Institution or Investigator from taking any action which is, in the reasonable medical judgment of the Study team members, in the Study subject's best interest. Any time Actinium or Aptiv becomes aware of a significant Study subject safety issue it will communicate such information to Institution. Actinium further agrees to promptly report to Institution the results of any monitoring reports that could affect the safety of Study participants, influence the conduct of the Study, alter the Institutional Review Board ("IRB") approval to continue the Study, and/or affect the willingness of Study Subjects to continue in the Study. During the Study and after its completion, Actinium shall promptly report to Institution and the Investigator any Study results that could directly affect the safety or medical care of Study Subjects.. Institution and the Principal Investigator shall cooperate with Actinium/Aptiv and/or its designee in the performance of its duties as study monitor. Actinium/Aptiv's rights in this Section shall be subject to Actinium/Aptv's compliance with Institution's reasonable measures for purposes of confidentiality, safety, and security, and will be further subject to Actinium/Aptiv's compliance with Institution's premises rules that are generally applicable to all persons at Institution's facilities. Should Actinium/Aptiv utilize one or more third party(s) in exercising its rights in this paragraph, Actinium/Aptiv certifies that such party(s) shall be subject to an obligation of confidentiality consistent with the obligations of confidentiality required of Actinium hereunder and such third party(s) shall be subject to any and all conditions up Actinium/Aptiv' s rights that are set forth in this Section, If Actinium/Aptv obtains, learns of, comes in contact with, or otherwise has access to any patient health and medical information, Actinium/Aptv will keep such information confidential and will comply with all applicable laws regarding the confidentiality of such information and Actinium/Aptv will not use or disclose such patient health and medical information in a manner that would violate any applicable law (including the HIPAA Privacy Regulations) if such use or disclosure were made by Institution.

5. | Responsibilities of Site

| a. | The Site certifies and represents that Investigator is an employee of the Site, and is sufficiently qualified by training and experience to conduct the Study using the Study Drug. A true and complete copy of the Investigator's current curriculum vitae is attached as Exhibit B and made part of this Agreement.
| b. | The Site certifies that the Investigator to its knowledge has never been involved in any investigation or research at the Site which was terminated by the FDA, National Institutes of Health (NTH) or any sponsor for non-compliance.
| c. | The Site certifies and represents that Investigator to its knowledge has not been disbarred under Section 306 of the Federal Food, Drug and Cosmetic Act, or any other section of said act or its successor, and further, that the Investigator to its knowledge will not use in any capacity, the services of any individual or entity which has been so disbarred, in any aspect of this Study. The Site agrees to notify Actinium immediately if the Investigator or any individual or entity involved in this Study is the subject of a disbarment proceeding or becomes disbarred.
| d. | In addition to and without limiting the obligations of Section 2a above, the Site agrees to conduct the Study in strict accordance with this Agreement, the Protocol, all associated documentation provided by Aptiv (e.g. CRF, CRF Completion guidelines, User Manuals, and Regulatory Binder documentation), applicable regulations, and all conditions of approval imposed by the reviewing IRB or FDA. The Site shall permit the use of the Study Drug only on Qualified Subjects under Investigator's personal supervision only for the purpose of the Study. The Site shall not supply the Study Drug to any other person or entity not authorized under FDA regulation to receive it, nor to any person for any purpose other than the Study. The Site shall not modify or alter the Study Drug. The Site shall maintain proper control of all Study Drug inventory and return of unused quantities of Study Drug as required by regulation and directed by Actinium and at the reasonable expense of Actinium.

March 1, 2012 Page 4 of 14

|  | The Site agrees that the Investigator will personally supervise or perform all testing of the Study Drug involving human subjects.
| e. | The Site agrees to maintain all records and make all reports as required by regulation, the Study, the IRB and this Agreement.
| f. | The Site agrees to use its reasonable best efforts, on a diligent and continuous basis, to recruit Qualified Subjects, to prepare true and accurate Case Report Forms, to make all required reports, to complete the Study within the time limits set forth in this Agreement, and to perform all long-term follow-up examinations, visits and data collection as required by the Study and/or regulation from time to time. In addition, all CRF and Study Data shall be submitted to Aptiv within ten (10) days of written request. This provision shall survive termination or expiration of this Agreement.
| g. | The Site shall exclusively use the Informed Consent. The Site agrees that the 1RB approved consent form must be provided to and acknowledged by Actinium prior to use. The Site agrees that the Investigator shall not conduct any screening procedures, enroll any Potential Subject nor use the Study Drug on any Potential Subject who has not given written consent by signing and dating the specified Informed Consent form. The Site agrees that Investigator shall personally ensure that all the requirements for obtaining informed consent are met.
| h. | The Site agrees that Investigator will follow good medical practice and exercise the customary standard of care practiced in his professional specialty.
| i. | The Site ensures that Investigator will provide sufficient accurate financial disclosure information to allow Actinium or Aptly to submit a complete and accurate certification or disclosure statement as required under 21 CFR part 54, as it may be amended from time to time. Further, the Site agrees that the Investigator shall promptly update this financial disclosure information if any relevant changes occur during the course of the Study and for one (1) year following completion of the study. The Site also agrees that Investigator will update this financial disclosure information promptly after the request by Actinium or Aptiv. The Site understands that this information shall be submitted in any marketing application involving the Study Drug. This provision shall survive termination or expiration of this Agreement.
| j. | The Site agrees to provide sufficient resources to the IRB to enable the IRB to operate as required by law, regulation and its own procedures.
| k. | During the Study, and subject to the terms of this Agreement, Site agrees to use reasonable efforts to cause the Investigator to conduct the Study pursuant to the Protocol and to provide to Investigator reasonable access to all Site facilities, staff and resources which the Investigator determines necessary or desirable to the conduct of the Study. Without limiting the foregoing, the Site agrees to make available a Study coordinator, qualified by training and experience and reasonably acceptable to Actinium and Aptiv, to manage all administrative functions of the Study, including but not limited to, meeting with Actinium and Aptiv. All such Site facilities, staff and resources used in the Study are subject to the supervision of the Investigator.
| 1. | The Site agrees to provide the facilities necessary to the conduct of the Study, and to notify Actinium and Aptiv promptly, but no later than 2 administrative business days after the discovery, of any failure of the Investigator, the Site or the 1RB itself, to follow any of the established protocols for the Study.
| m. | The Site agrees to allow Aptiv and Actinium reasonable access to the study site and to facilities and staff as reasonably needed to conduct long-term follow-up of Study subjects, at Actinium/Aptiv's expense. The Site will ensure that the Investigator will be reasonably available during normal regular business hours and at reasonable intervals to meet with a study monitor to review the status of the Study and discuss any pending issues. Aptiv will provide no less than thirty (30) days advance notice of monitoring visits and will use all reasonable efforts to coordinate the scheduling of the visits with the Investigator and Study Coordinator. This provision m shall be subject to Section 4d above.
| n. | The Site agrees to allow Actinium and Aptly reasonable access to Study Data, including without limitation, patient records (subject to patient consent), and Case Report Forms, as necessary for completion of the Study, long-term follow-up, and compliance efforts, at Actinium's expense.

March 1, 2012 Page 5 of 14

| o. | The Site certifies and represents that it will not knowingly use in the Study, in any capacity whatsoever, whether as employee, consultant, contractor or agent, the services of any individual or entity who has been disbarred under Section 306 of the Federal Food, Drug and Cosmetic Act, or any other section of said act or its successor. The Site agrees to notify Aptiv immediately if any individual or entity involved in this Study is the subject of a disbarment proceeding or becomes disbarred.
| P. | In the event the Investigator becomes unable to complete the Protocol for any reason, Site will, to the extent possible, propose a substitute Investigator with qualifications and experience at least equal to or greater than those of the Investigator for Actinium's approval, which approval shall not be unreasonably withheld. In the event Actinium and Site agree upon a substitute Investigator, this Agreement shall continue in full force and effect. If Actinium and Site are unable to agree on a substitute Investigator, this Agreement may be terminated in accordance with the provisions of this Agreement.
| q. | Subparagraphs 5J-5P shall survive termination or expiration of this Agreement.
| r. | The Site and Investigator agree to notify Aptiv and Actinium as soon as possible, but in no event later than twenty-four (24) administrative business hours after each discovery of a serious event in the Protocol permitted by 21 CFR 312.60(a)(2). The Investigator shall complete all reports when and in the manner required by 21 CFR 312.62 and 312.64. The Investigator shall make all other reports as required by 21 CFR 312.62 and 312.64.
| s. | The Site agrees to cooperate with any study monitor designated by Aptiv to monitor this Study (subject to Section 4b above). The Site agrees to cooperate with authorized FDA employees conducting an audit or inspection, in the manner required by 21 CFR 312.68. The Investigator shall promptly notify Actinium of any request for an audit of the Study by the Site, the FDA or any other governmental agency. If any inspection occurs and to the extent permitted by law, the Site will provide Actinium and Aptiv with copies of all auditor (including FDA and IRB) materials, correspondence, statements, forms and records that are received by the Investigator or the Site. Actinium and Aptiv shall assist the Investigator in responding to any FDA or IRB correspondence and promptly implementing any necessary corrective action. This provision shall survive termination or expiration of this Agreement.
| t. | The Site certifies that its Investigator has made all the necessary disclosures required regarding conflict of interest in connection with this Study.
| u. | The Site hereby assures Actinium that the Study will be reviewed and approved by its IRB before any Study Drug is tested on a human subject, and further, that said IRB is functioning in compliance with the applicable regulations and at all times. The Site shall provide, upon request, evidence of IRB approvals related to this Study in a timely manner, This provision shall survive termination or expiration of this Agreement. The Site certifies that the Site has not, except as has been previously disclosed to Actinium and Aptiv in writing, in the last five (5) years been involved in any study which was terminated by any IRB, the FDA, National Institutes of Health (NIH) or any sponsor for non-compliance.

6. | Payment

| a. | In support of the performance of the Study, Actinium will pay to Site, subject to the terms and conditions of this Agreement the sum of US$19,445.77 for each Completed Subject of the Study, as set forth in the Site Budget and Payment schedule, attached to and made part of this Agreement as Exhibit C. In no event shall payments to the Site exceed US$19,445.77 for each Completed Subject up to a maximum of sixty (60) Completed Subjects. All payments are gross in US Dollars; all approved invoices are net thirty (30) days.

March 1, 2012 Page 6 of 14
Payment of all sums due hereunder shall be made by check payable as follows:
The University of Texas, M.D. Anderson Cancer Center
P.O Box 4390
Houston, TX 77210-4390
Attn. Grants and Contracts Accounting
Tax ID: 74-6001118

| b. | Any additional payments must be approved in advance by Actinium in writing.
| c. | The Site agrees to be responsible for invoicing Actinium in accordance with the Budget and Payment Schedule (Exhibit C).
| d. | Any equipment (except for the Study Drug) purchased by the Site as part of the Protocol shall be owned by the Site, shall be physically located at Site, and shall remain the property of Site following completion of the Study.
| e. | In no event is Actinium required to make any payment for any costs incurred with respect to Non-Qualified Subjects entered into the treatment phase of the Study or for any Subject who has not given written Informed Consent to participate in the Study.
| f. | Nothing contained herein shall be construed as requiring Site, the Investigator or any Site research staff to work on any project or process which is knowingly prohibited by law or by any international treaty to which the United States of America is a party, or which may be harmful or detrimental to public health, patient safety or good clinical care or which may be considered to be immoral. No payment is subject to submission of favorable clinical results or evaluations.
| g. | Notwithstanding the foregoing, in no event shall any payment be made under this Agreement which is contrary to 42 USC 1320a-7b, as it or any successor law may be in effect from time to time. In accordance with the statute, in no event shall the Investigator receive any payment, royalty, form of compensation, or remuneration of any nature, sort or description, for any use of all or any portion of the Study Drug by any hospital, clinic or other Site where he works. In no event shall any request for reimbursement or payment under any private or public health insurance carrier be made which is contrary to law.

7. | Publications

| Actinium acknowledge that it is Site's policy that the results of the Study must be publishable and the Investigator and others employed by Site or who are engaged in the Study be permitted to present at symposia, national or regional professional meetings and to publish in journals, theses or dissertations or otherwise in their sole discretion, the methods and results of the Study.
| The parties recognize that because this is a multi-center Study, there is a need for a coordinated approach to any publication or public disclosure of the data or results of this Study. To that end, there will be no publication or public disclosure of such data or results by the Site or Investigator until a multi-center publication is submitted for publication or presentation by Actinium, or its designee. However, if no multi-site publication is submitted by Actinium or its designee within twelve (12) months of the completion termination, or abandonment of the Study from all sites, the Site and the Investigator shall be free to publish for non-commercial purposes the Study results from there Site as follows. If the Site or the Investigator wishes to publish or publicly disclose Study and data or results the Site will submit any proposed manuscript or publication to Actinium for comment at least thirty (30) days prior to its submission for publication or other disclosure. The Site will review and consider in good faith comments received from Actinium during such thirty (30) day period. If requested to do so by Actinium, Site agrees to remove confidential information provided by Actinium prior to submitting the manuscript or publication, excluding Study data / results or any other information that may be required by the publishing source. Actinium will make every reasonable attempt to notify the Site within said thirty (30) days of receipt of the proposed publication whether it is desirable to file a patent application on any inventions contained in the proposed publication. In the event Actinium decides to pursue patent protection, Actinium shall have the right to defer publication for an additional thirty (30) days to permit the filing of any desired patent application.

March 1, 2012 Page 7 of 14

8. | Confidential Information

| a. | The parties acknowledge that as part of the scientific collaboration between Actinium, Aptiv and the Site in connection with the Study, Aptiv or Actinium may find it necessary to disclose certain confidential and proprietary information and trade secrets of Actinium and/or Aptiv. Such confidential and proprietary information includes, without limitation, the Protocol, all intellectual property contained in the Study Drug, the design and manufacturing processes utilized to produce and test the Study Drug, the identity of Actinium's suppliers, data concerning scientific discoveries made by Actinium and/or Aptiv; Actinium's manufacturing strategies and processes; Actinium's marketing plans; data from Actinium's evaluations in animals and humans; Actinium's strategy for or status of regulatory approval; or Actinium's forecasts of sales and sales data, and any other information which by its nature would be considered confidential (hereafter referred to collectively as "Actinium Confidential Information"). Such Actinium Confidential Information shall remain the confidential and proprietary property of Actinium and shall be disclosed to Site's employees, affiliates or agents on a "need to know" basis, and who are bound by similar obligations to protect the Actinium Confidential Information from unauthorized disclosure.
| b. | The Site may find it necessary to disclose certain confidential and proprietary information and trade secrets of Site to Actinium or Aptiv Such confidential and proprietary information includes, any data, records or other information disclosed to Actinium or Aptiv, or its designee, (hereinafter collectively, "Site Confidential Information"). Such Site Confidential Information shall remain the confidential and proprietary property of Site and shall be disclosed to Actinium/Aptiv or its designees, employees, affiliates or agents on a "need to know" basis.
| c. | Each party hereby agrees that for a period of five (5) years after the disclosure of such confidential information or the termination of the Agreement neither party shall (i) publicly divulge, disseminate, publish or otherwise disclose any of the other party's confidential information without prior written consent; (ii) limit access to each party's confidential information to those of the other party's, co-workers and staff who are involved in the Study and have a need for such confidential information in connection with the conduct of the Study, and (iii) cause the return to the other party ( at the reasonable expense of the requesting party ), as the case may be, any and all documents, drawings, sketches, designs, products or samples containing confidential information, together with any copies thereof, promptly upon termination of this Agreement or upon the other party's request therefore., provided that to the extent permitted by all applicable laws and regulations, such obligations undertaken by the said party shall remain in force with respect to the Chemical Manufacturing and Control Section, Toxicity Studies or Performance Studies.
| d. | Notwithstanding the foregoing, the obligations of confidentiality and nondisclosure shall not apply to the following information:

|  | (1) | Information that was in the public domain prior to the date of disclosure to the receiving party coming into possession thereof, or becomes part of the public domain by publication or otherwise through no fault or unauthorized act or omission on the part of the receiving party;

March 1, 2012 Page 8 of 14

|  | (2) | Information that is disclosed to the receiving party by a third party legally entitled to disclose such information, as demonstrated by competent evidence;
|  | (3) | Information that was rightfully in the possession of or already known to the receiving party as demonstrated by prior written records;
|  | (4) | Information that is independently developed by the receiving party without reference to any confidential information, as demonstrated by competent evidence; or
|  | (5) | Information that is required to be disclosed to a government authority or by order of a court of competent jurisdiction, provided that (a) such disclosure is subject to all applicable governmental or judicial protection available for like material; (b) reasonable advance notice is given to the disclosing party and disclosing party is provided with an opportunity to comment on such proposed disclosure; and (c) the receiving party take all reasonable steps to limit the scope of such disclosure.
|  | (6) | Information that is required to be disclosed in order to obtain consent from patients or subjects who may wish to enroll in the Study, provided, however that the information will be disclosed only to the extent necessary and will not be provided in answer to unsolicited inquires by telephone or to individuals who are not eligible Study candidates, provided further, however, that such information disclosed to a patient or subject shall continue to be Confidential Information under this Agreement.

| e. | Site, in accordance with its policies and procedures, may post the Protocol on its internal database (referred to as "FYI") and share the Protocol, or portions thereof, as necessary i) to comply with all applicable laws and regulations; ii) for internal patient care billing audits with Site's affiliates, and iii) to provide information to third party payors as necessary, in connection with the processing or payment of a claim submitted in relation to a Study subject. Site shall also be allowed to post a synopsis of the Protocol on its recruitment website.

In addition, the parties agree that the Investigator may disclose the title of the Study on his curriculum vitae and grant application(s).

9. | Intellectual Property

The parties acknowledge that it is unlikely that an invention will result during the performance of the Study. Site, on behalf of itself and its employees, consultants and agents, agree that excluding medical records and Lab notebooks, all research data and results which is conceived and/or reduced to practice during the conduct of the Study and arising from the performance of the Study ("Intellectual Property") shall be property of Actinium, subject to Institution's right to use the results and data of the Study for its internal research, academic, and patient-care purposes. The Site shall promptly disclose all said Intellectual Property to Aptiv after notification of any such Intellectual Property is received by Institution's Office of Technology Commercialization. The Site also represents that it has obtained sufficient authority to make this grant from all individuals that Site makes available to perform this Agreement and to provide good and clear title to Actinium. Additionally, Site, on behalf of itself and all of its employees, contractors and agents, hereby grants Actinium the right to file, prosecute and defend any such patent applications, at Actinium's own cost and expense. Site agrees to render all reasonable assistance to Actinium in the filing, prosecution and defense of any such patent application at Actinium's own cost and expense.
The parties further acknowledge and agree that Actinium is the owner or authorized licensee of the Study Drug. Neither Site nor Investigator shall obtain any license to make, have made, sell, distribute, rent, lease, or otherwise transfer or use the Study Drug or Actinium Confidential Information, or their derivatives. Actinium Confidential Information is licensed for use only on and in combination with the Study Drug, and may not be used on or with third party products without Actinium's prior express written permission. This Agreement grants no implied rights.

March 1, 2012 Page 9 of 14
Aptly on behalf of Actinium, hereby grants to Site a non-exclusive royalty free license to the Intellectual Property for Site's own internal nonprofit research, patient care,and education related purposes.

10. | Indemnification

| a. | Site shall, to the extent authorized under the Constitution and laws of the State of Texas, indemnify and hold harmless from liability resulting from the negligent acts or omissions of Site, its agents or employees pertaining to the activities to be carried out pursuant to the obligations of this Agreement; provided, however, that Site shall not hold Actinium harmless from claims arising out of the negligence or willful malfeasance of Actinium, its officers, agents, or employees, or any person or entity not subject to Actinium's supervision or control.

Actinium shall indemnify and hold harmless System, Site, their Regents, officers, agents and employees from any liability or loss resulting from judgments or claims against them arising out of the activities to be carried out pursuant to the obligations of this Agreement, including but not limited to, the use by Actinium of the results of the Study; provided, however, that the following is excluded from Actinium 's obligation to indemnify and hold harmless:

| a. | the negligent failure of Site to comply with any applicable governmental requirements or to adhere to the terms of the Protocol; or

| b. | the negligence or willful malfeasance by a Regent, officer, agent, or employee of Site or System.

This obligation to indemnify is subject to the Site Indemnitees giving Actinium written notice of any claim, suit or demand and full control of any defense and settlements of such claim, provided, however, such settlements shall not require Site to contribute to the settlements, admit fault or require Site to change its operations or business practices, suit or demand. The Site Indemnitees will also notify Actinium promptly in the event any one of them becomes aware of any potential claim, or likelihood of any potential claim of indemnification rights under this Section. Site Indemnitees will reasonably cooperate, at Actinium's expense, in the defense or settlement of any claim or action. This provision shall be subject to the statutory duties of the Texas Attorney General.
This Paragraph shall survive expiration or termination of this Agreement.

| c. | Study-Related Injury.

Subject to Section 10(b), above, Actinium agrees to pay for all reasonable costs incurred for the care and treatment of any illness or injury to a Subject resulting from his or her participation in the Study.

February 14, 2012 Page 10 of 14

11. | Insurance

Each Party will maintain in effect appropriate insurance or self-insurance in amounts sufficient to meet its liability obligations under this Agreement. Each Party's coverage will comply with applicable laws, rules, regulations and insurance guidelines. Notwithstanding the foregoing, Institution, as a member institution of System, is an agency of the State of Texas and is self-insured pursuant to The University of Texas System Professional Medical Malpractice Self-Insurance Plan, under the authority of Section 59.01, Texas Education Code. Institution has and will maintain in force during the term of this Agreement adequate insurance or financial resources to cover its indemnification obligations hereunder.

12. | Term and Termination

Unless earlier terminated in accordance with its terms, this Agreement shall commence on the date when it is signed by all parties, (the "Effective Date", and shall continue in full force and effect until two (2) years after the Study has been completed.

| a. | This Agreement shall be terminated immediately in the event that: 1) the authorization and IND issued by the FDA is withdrawn, 2) the approval of the IRB is withdrawn; or 3) the Investigator has not included any Qualified Subjects in the Study in accordance with Paragraph 3.c. and after the Study has been open to enrollment for twenty-four (24) months.
| b. | Except as otherwise provided in this section, any party may terminate this Agreement uponthirty (30) days prior written notice in the event of any material breach by another party of any material term or condition hereof; provided such breach is not cured within said thirty ( 30) day notice period.
| c. | Any party may terminate or suspend this Study immediately for the safety of Subjects, pursuant to applicable regulations. In such case, the party terminating or suspending the study will provide prompt written notice to the other party.
| d. | Any party may terminate this Agreement upon written notice immediately in the event a party engages in criminal, unprofessional or fraudulent conduct.
| e. | Actinium may terminate this Agreement upon thirty ( 30) prior written notice in the event that: 1) the Protocol is suspended by the IRB; 2) the Principal Investigator is unable to complete the Study and a substitute Principal Investigator cannot be agreed upon, or 3) if circumstances reasonably beyond Site's control preclude the Site from continuing the Study, and such suspension of the Study exceeds sixty (60) consecutive days or ninety (90) days in the aggregate in any year during the term (or renewal) of this Agreement.
| f. | Actinium may terminate this Agreement at any time upon one (I) month prior written notice to the Site. In such case, Site may terminate this Agreement at any time upon thirty (30) days prior written notice to Actinium.
| g. | Any provision of this Agreement, which provides continuous enforcement or operation thereof after the termination hereof, shall survive the termination of this agreement.

13. | Effect of Termination

Except as otherwise provided herein, termination of this Agreement shall not be construed to release either party from any obligation hereunder which has matured prior to the date of said termination. Upon termination of this Agreement, Site shall promptly return to Actinium and Aptiv the Study Drug, Study Data, including without limitation, all CRF and Actinium Confidential Information at Actinium's or Aptiv's expense. In the event of early termination, Actinium shall liable for all reasonable costs incurred or obligated by Institution at the time of such termination.

February 14, 2012 Page 11 of 14

14. | Diversity in Study Population - Translation Services

The Site endorses the National Institute of Health's policy concerning the inclusion of minorities in study populations. The Investigator is encouraged to recruit patients into the Study without regard to ethnic background. The Site shall provide the consent form applicable to the Study in written form translated to the appropriate language to any non-English speaking minorities included in the Study. Any cost incurred by the Site for the development of a translated informed consent from will be agreed upon in advance and reimbursed by Actinium or Aptiv. The Site shall present Actinium or Aptiv with an invoice for translation services which Actinium or Aptiv shall reimburse to the Site within thirty (30) days of receipt. The parties acknowledge that said translation costs are not included in the Study budget set out in Appendix B and are not included in the Total Cost of the Study.

15. | Communications

All medical/scientific and other communications, reports and notices shall be delivered by hand, by facsimile, by secure electronic means or sent by first class mail postage prepaid and addressed as follows:

| If to Aptiv: | Anthony Apicella
|  | Aptiv Solutions 225 Turnpike Rd.
|  | Sothborough, MA 01772
| If to Actinium: | Dragan Cicic, CEO 391 Lafayette Street Newark, NJ 07105
| If to Site : | M.D. Anderson Cancer Center
|  | 1515 Holcombe Blvd. Unit 1676
|  | Houston, TX 77030
|  | Attn: Renee Gonzales, Sponsored Programs
| With a Copy to: | M.D. Anderson Cancer Center 1020 Holcombe Blvd. Suite 1500 Houston, TX 77030 Attn: Chief Legal Officer
| If to Investigator: | M.D. Anderson Cancer Center 1515 Holcombe Blvd. Unit 0428 Houston, TX 77030

In no event shall Site or the Investigator file any communication they are legally required to file with the FDA or any other regulatory agency, without first notifying Aptiv, unless otherwise requested by the FDA or other regulatory agency.

November 16, 2012 Page 12 of 14

16. | Use of Names

Except as otherwise required by law, each party agrees not to use or cite in any manner the name of the other party or its employees in any commercial or non-commercial advertising, article, press release or in any other forms of writing or publication medium without the prior written permission of the party or individi ial whose name or employee's name is to be used.

17. | General Provisions

| a. | All rights and remedies hereunder are exclusive and not cumulative.
| b. | This Agreement may be amended only by written agreement signed by all parties.
| c. | It is expressly agreed by the parties hereto that the Site, the Investigator and Aptiv are independent contractors and nothing in this Agreement is intended to create an employer relationship, joint venture, or partnerships between the parties. No party has the authority to bind any other.
| d. | This Agreement, including all exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all proposal, negotiations and other communications between the parties, whether written or oral, with respect to the subject matter hereof.
| e. | If any provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be impaired thereby, and the party against whom the holding is made, shall be entitled to substitute a similar provision that preserves the benefit of the bargain.
| f. | The failure of any party to insist on strict performance of any provision of this Agreement or exercise any right hereunder will not constitute a waiver of that provision or right.
| g. | This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against the party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument.
| h. | Each party hereto agrees to execute, acknowledge and deliver such further instruments and do all such further acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
| h. | The paragraph headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.
| i. | Site is an agency of the state of Texas, and under the constitution and laws of the state of Texas, Site possess certain rights and privileges and is subject to certain limitations and restrictions. Notwithstanding any provision hereof, nothing herein in intended to be, nor may it be construed to be, a waiver of the sovereign immunity of the state of Texas or a prospective waiver or restriction of any of the rights, remedies, claims, and privileges of the state of Texas. Moreover, notwithstanding the generality or specificity of any provision hereof, the provisions of this Agreement enforceable only to the extent authorized by the constitution and laws of the state of Texas; accordingly, the provisions of this Agreement will not be enforceable to the extent any provision (1) conflicts with or is not authorized by the constitution or laws of the state of Texas, or (2) Site did not have the power or authority to agree to such provision.

November 16, 2012 Page 13 of 14

| j. | Neither Party will be required to perform any act or to refrain from any act in violation of any applicable state or federal law. In this regard, this Agreement are subject to, and the Parties will comply with all applicable local, state, and federal laws, statutes, rules, and regulations, and all applicable judicial or administrative orders. Any provision of any law, statute, regulation, or order that is inconsistent with any provision of this Agreement shall be deemed to have superseded the terms of this Agreement. The Parties, however, will use their reasonable efforts to accommodate the terms and intent of this Agreement to the greatest extent possible consistent with the requirements of the law and negotiate in good faith toward amendment of this Agreement in such respect. If the Parties are unable to agree to new or modified terms as required to bring the entire Agreement into compliance, either Party may terminate this Agreement on sixty days written notice to the other Party.

November 16, 2012 Page 14 of 14
IN WITNESS WHEREOF, the parties intending to be legally bound have caused this Agreement to be executed by their duly authorized representatives or, in the case of the Investigator, have duly executed this Agreement, on the dates stated beneath their names:
THE UNIVERSITY OF TEXAS M.D ANDERSON CANCER CENTER READ AND ACKNOWLEDGED

READ AND ACKNOWLEDGE |  |  |
/s/ Renee Gonzales |  |  |
Name: Renee Gonzales |  |  |
Title: Assistant Ditector, Sponsored programs |  |  |
Dated: | 8-28-12 |  |  |

ACTINIUM PHARMACEUTICALS, INC.
Accepted by:

/s/ Dragon Cicici |  |  |
Name: Dragan Cicici |  |  |
Title: COO |  |  |
Dated: | 9-5-2012 |  |  |

Read and Understood by:
INVESTIGATOR:
Name: Farhad Ravandi-Kashani, MD

Investigator: Farhad Ravandi-Kashani Dated: 8/27/12

[Notary Seal]